Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Agios Pharmaceuticals, Astex Pharmaceuticals, Inc, Bristol Myers Squibb and Takeda Oncology.

Community Practice Connections™: New Horizons in the Management of Myelodysplastic Syndromes: Exploring Advancements from Low- to High-Risk Disease

Release Date: November 30, 2020
Expiration Date: November 30, 2021

Activity Overview

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of disorders of the blood-forming stem cells in the bone marrow and results in lower than normal numbers of one or more types of blood cells. A rapidly evolving treatment landscape and changes to prognostic scoring systems have created a practice gap for healthcare providers treating patients with MDS.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the New Horizons in the Management of Myelodysplastic Syndromes: Exploring Advancements from Low- to High-Risk Disease symposium, held in August 2020. This unique and engaging multi-media activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with MDS, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live webcast and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Agios Pharmaceuticals, Astex Pharmaceuticals, Inc, Bristol Myers Squibb and Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward hematologists, medical oncologists, nurse practitioners, nurses, and fellows who treat patients with myelodysplastic syndromes (MDS). Physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of MDS will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Review available tools for MDS classification and risk stratification, based on morphological, clinical, and cytogenetic criteria
  • Outline strategies to individualize therapy in MDS based on risk stratification and patient comorbidities
  • Apply recent clinical trial findings to real-world practice for the management of MDS
  • Summarize data from recent clinical trials evaluating efficacy and safety of novel therapies to treat MDS from low- to high- risk disease

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Guillermo Garcia-Manero, MD
Guillermo Garcia-Manero, MD
Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: AbbVie, Amphivena Therapeutics, Astex Pharmaceuticals, Celgene/Bristol Myers Squibb, H3 Biomedicine, Helsinn Advanced Synthesis SA, Merck, Novartis, Onconova Therapeutics; Consultant: Astex Pharmaceuticals, Bristol Myers Squibb, Helsinn Advanced Synthesis SA.


Amy E. DeZern, MD, MHS
Amy E. DeZern, MD, MHS
Associate Professor of Oncology and Medicine
Division of Hematologic Malignancies
The Johns Hopkins University School of Medicine
Baltimore, MD

Disclosures: Consultant: Celgene/Bristol Myers Squibb.

David P. Steensma, MD
David P. Steensma, MD
Edward P. Evans Chair in MDS Research
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: Aprea Therapeutics, H3 Biosciences; Consultant: Celgene/Bristol Myers Squibb, Novartis, Onconova Therapeutics, PharmaEssentia, Takeda.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By